| Ma, Ding |
L-MOCA, NCT03534453: Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy |
|
|
| Active, not recruiting | 3 | 229 | RoW | Olaparib 300mg tablets | AstraZeneca | Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy, Platinum Sensitive | 12/24 | 12/24 | | |
BGB-290-302, NCT03519230: Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer |
|
|
| Active, not recruiting | 3 | 224 | RoW | Pamiparib capsule, BGB-290, Placebo capsule | BeiGene | Ovarian Cancer | 06/25 | 06/26 | | |
|
|
NCT04723875: Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline |
|
|
| Active, not recruiting | 3 | 306 | RoW | Paclitaxel or docetaxel + Cisplatin or carboplatin | Huazhong University of Science and Technology, Women's Hospital School Of Medicine Zhejiang University, Qilu Hospital of Shandong University, Obstetrics & Gynecology Hospital of Fudan University, First Affiliated Hospital of Chongqing Medical University, Hunan Cancer Hospital, The Third Xiangya Hospital of Central South University | Uterine Cervical Neoplasms, Cervical Cancer | 01/26 | 01/26 | | |
NCT04733820: Clinical Efficacy of Adjuvant Chemotherapy in Patients With Locally Advanced Cervical Cancer Who Did Not Meet the NCCN Guidelines for Adjuvant Treatment After NACT Combined With Surgery |
|
|
| Recruiting | 3 | 340 | RoW | Adjuvant chemotherapy | Huazhong University of Science and Technology, Women's Hospital School Of Medicine Zhejiang University, Qilu Hospital of Shandong University, Obstetrics & Gynecology Hospital of Fudan University, First Affiliated Hospital of Chongqing Medical University, Hunan Cancer Hospital, The Third Xiangya Hospital of Central South University | Uterine Cervical Neoplasms, Cervical Cancer | 02/28 | 02/28 | | |
| Recruiting | 2/3 | 440 | RoW | Camrelizumab, Cisplatin, Nab paclitaxel, Radical surgery, external beam radiation therapy (EBRT) + brachytherapy | Tongji Hospital, Southwest Hospital, China, Women Hospital, School of Medicine, Zhejiang University, Anhui Provincial Cancer Hospital, Sichuan Cancer Hospital and Research Institute, Qilu Hospital of Shandong University, Beijing Friendship Hospital, Tianjin Medical University General Hospital, West China Second University Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Xiangya Hospital of Central South University, Gansu Provincial Maternal and Child Health Care Hospital, Zhejiang Cancer Hospital, Shengjing Hospital, Cancer Hospital of Guangxi Medical University | Cervical Cancer, Locally Advanced Cervical Cancer, Concurrent Chemoradiotherapy, Neoadjuvant Chemoimmunotherapy | 03/31 | 03/31 | | |
NACI, NCT04516616: Pd-1 Antibody Combined Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer |
|
|
| Active, not recruiting | 2 | 85 | RoW | Cisplatin+Albumin-bound paclitaxel (1 cycle) and PD-1 monoclonal antibody+Cisplatin+Albumin-bound paclitaxel (2 cycles) | Huazhong University of Science and Technology, Women's Hospital School Of Medicine Zhejiang University, Qilu Hospital of Shandong University, Obstetrics & Gynecology Hospital of Fudan University, First Affiliated Hospital of Chongqing Medical University, Army Medical University, China, Peking University People's Hospital, Tianjin Medical University General Hospital, The Second Affiliated Hospital of Harbin Medical University, Chongqing University Cancer Hospital, The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial) | Uterine Cervical Neoplasm, Uterine Cervical Cancer, Cervical Cancer | 04/23 | 07/28 | | |
NCT04590599: A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy |
|
|
| Completed | 2 | 205 | RoW | IBI310, Placebo, Sintilimab, IBI308 | Innovent Biologics (Suzhou) Co. Ltd. | Advanced Cervical Cancer | 11/23 | 11/23 | | |
| Recruiting | 2 | 40 | RoW | Camrelizumab, Cisplatin, Nab paclitaxel, biopsy | Tongji Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Women Hospital, School of Medicine, Zhejiang University, Third Military Medical University, Beijing Friendship Hospital, Sichuan Cancer Hospital and Research Institute, Tianjin Medical University, West China Second University Hospital, Xiangya Hospital of Central South University, Qilu Hospital of Shandong University, Gansu Cancer Hospital, Zhejiang Cancer Hospital, Shengjing Hospital, Anhui Provincial Cancer Hospital | Cervical Cancer, Neoadjuvant Chemoimmunotherapy, Fertility Preservation | 12/25 | 12/30 | | |
NCT06289751: Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer |
|
|
| Recruiting | 2 | 50 | RoW | Cadonilimab, Cadonilimab Injection, AK104, Paclitaxel-albumin, Injectable paclitaxel (albumin bound), Cisplatin, Cisplatin injection, Extrafascial hysterectomy, Radical hysterectomy, Cone biopsy | Tongji Hospital, The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial), Women Hospital, School of Medicine, Zhejiang University, Southwest Hospital, China, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Sichuan Cancer Hospital and Research Institute, Qilu Hospital of Shandong University, Beijing Friendship Hospital, Tianjin Medical University, West China Second University Hospital, Xiangya Hospital of Central South University, Gansu Provincial Maternal and Child Health Care Hospital, Zhejiang Cancer Hospital, Shengjing Hospital | Cervical Cancer, Neoadjuvant Chemoimmunotherapy, Radical Hysterectomy, Extrafascial Hysterectomy | 03/26 | 01/31 | | |
| Recruiting | 2 | 40 | RoW | Camrelizumab, SHR-1210, Paclitaxel-albumin, Injectable paclitaxel (albumin bound), Cisplatin, Cisplatin injection, radical surgery | Tongji Hospital, Southwest Hospital, China, Women Hospital, School of Medicine, Zhejiang University, Anhui Provincial Cancer Hospital, Sichuan Cancer Hospital and Research Institute, Gansu Provincial Maternal and Child Health Care Hospital, Beijing Friendship Hospital, Tianjin Medical University General Hospital, Xiangya Hospital of Central South University, West China Second University Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Zhejiang Cancer Hospital, Shengjing Hospital, Qilu Hospital of Shandong University, Cancer Hospital of Guangxi Medical University | Cervical Cancer, Locally Advanced Cervical Cancer, PD-L1 Negative, Neoadjuvant Chemoimmunotherapy | 12/25 | 12/30 | | |
NCT05325229: A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer |
|
|
| Recruiting | 2 | 94 | RoW | Docetaxel for injection (Albumin-bound), Bevacizumab | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Platinum-resistant Recurrent Ovarian Cancer | 12/24 | 12/24 | | |
NCT03226470: Study of Targeted Therapy Using Transcription Activator-like Effector Nucleases in Cervical Precancerous Lesions |
|
|
| Recruiting | 1 | 40 | RoW | T512, TALEN-T512 | Huazhong University of Science and Technology | Human Papillomavirus-Related Malignant Neoplasm | 02/22 | 06/22 | | |
NCT06336707: HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 1048 | RoW | HS-20089, Adebrelimab, Bevacizumab, Cisplatin / carboplatin | Hansoh BioMedical R&D Company | Advanced Solid Tumors | 04/26 | 04/28 | | |
RWS-01, NCT03955185: Clinical Trial of Minimally Invasive Surgery Versus Abdominal Surgery in Patients With Early Stage Cervical Cancer |
|
|
| Recruiting | N/A | 2000 | RoW | minimally invasive surgery, open abdominal surgery | Ding Ma | Uterine Cervical Neoplasm | 05/22 | 05/24 | | |
| Recruiting | N/A | 590 | RoW | Vaginal brachytherapy, External beam radiotherapy, Observation, Chemoradiation therapy | Women's Hospital School Of Medicine Zhejiang University, Tongji Hospital, Qilu Hospital of Shandong University, Obstetrics & Gynecology Hospital of Fudan University, Sun Yat-sen University, Peking University People's Hospital, Shanghai First Maternity and Infant Hospital, Xiangya Hospital of Central South University, Anhui Provincial Cancer Hospital, Ningbo Women & Children's Hospital, Ningbo No. 1 Hospital | Endometrial Cancer Stage I, Endometrial Cancer Stage II | 12/24 | 01/27 | | |
NCT05570331: Clinical Evaluation of HPV Integration Triage for Detection of Cervical Precancer in HPV-positive Women |
|
|
| Recruiting | N/A | 2200 | RoW | HPV integration test | Ding Ma | HPV Infection, Cervical Cancer | 02/23 | 12/25 | | |
NCT04974424: Early Warning Model of Susceptibility and High-risk Population of Cervical Cancer Related to HPV |
|
|
| Recruiting | N/A | 20000 | RoW | | Huazhong University of Science and Technology, Women's Hospital School Of Medicine Zhejiang University, Obstetrics & Gynecology Hospital of Fudan University, Qilu Hospital of Shandong University, Wuhan Central Hospital, Third Military Medical University, Xiangyang Central Hospital, Shenzhen Second People's Hospital | Uterine Cervical Neoplasm, Uterine Cervical Cancer, Cervical Cancer | 12/23 | 12/23 | | |
| Zang, Rongyu |
| Active, not recruiting | 3 | 356 | RoW | Secondary Cytoreductive Surgery, Maximum effort cytoreductive surgery, Salvage Chemotherapy, second line chemotherapy | Shanghai Gynecologic Oncology Group, Fudan University, Zhejiang Cancer Hospital, Shanghai Zhongshan Hospital, Sun Yat-sen University | Ovarian Epithelial Cancer Recurrent, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma | 12/19 | 12/22 | | |
NCT02859038: Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY) |
|
|
| Recruiting | 3 | 488 | RoW | Upfront cytoreductive surgery, Primary debulking surgery, PDS, Interval debulking surgery, NACT-IDS | Shanghai Gynecologic Oncology Group | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma | 06/23 | 06/23 | | |
| Recruiting | 2 | 167 | RoW | Surgery, secondary cytoreduction, carboplatin/taxane, carboplatin/gemcitabine, cisplatin/gemcitabine, liposome doxorubicin/carboplatin..., third-line therapy, Niraparib, maintenance therapy | Shanghai Gynecologic Oncology Group, Fudan University, Shanghai Jiao Tong University School of Medicine, Zhejiang Cancer Hospital, Sun Yat-sen University | Ovarian Cancer Recurrent, Fallopian Tube Cancer, Primary Peritoneal Carcinoma | 06/25 | 12/26 | | |
NCT05236686: Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer |
|
|
| Not yet recruiting | 2 | 69 | RoW | Hepato-celiac lymphadenectomy | Shanghai Gynecologic Oncology Group, Fudan University | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma | 12/25 | 12/25 | | |
NCT06602063: Surgery for Ovarian Cancer After PARPi Therapy in Precision |
|
|
| Not yet recruiting | 1/2 | 33 | RoW | surgery/chemotherapy, Sintilimab | Shanghai Gynecologic Oncology Group, Shanghai Zhongshan Hospital, Tongji Hospital | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma | 09/29 | 09/29 | | |
| Lei, Ting |
NCT06023147: A Real-world Study of the Short-term Efficacy and Safety of E-TACE in Patients With Hepatocellular Carcinoma (HCC) |
|
|
| Not yet recruiting | N/A | 298 | RoW | E-TACE | Xuhua Duan | Hepatocellular Carcinoma | 09/24 | 09/25 | | |
| Recruiting | N/A | 200 | RoW | antibiotic-impregnated catheter | Integra LifeSciences Corporation | Hydrocephalus | 07/26 | 12/26 | | |
NCT05755516: Efficacy and Safety of the Self-expanding Intracranial Stent (Tonbridge) for Endovascular Treatment of Intracranial Aneurysms |
|
|
| Active, not recruiting | N/A | 204 | RoW | Self-expanding Intracranial Stent (Tonbridge), LVIS and LVIS Jr. (MicroVention) | Zhuhai Tonbridge Medical Tech. Co., Ltd. | Intracranial Aneurysm | 10/24 | 04/25 | | |
| Wang, Peng |
NCT04683406: A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A |
|
|
| Completed | 3 | 750 | RoW | ZSP1273 600 mg, Placebo to Oseltamivir, Oseltamivir(oral), Placebo to ZSP1273 | Guangdong Raynovent Biotech Co., Ltd | Influenza A | 04/23 | 05/23 | | |
| Not yet recruiting | 3 | 420 | RoW | Anlotinib hydrochloride capsule + TQB2450 injection, Chemotherapy drug | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Endometrial Cancer | 12/27 | 06/29 | | |
| Active, not recruiting | 3 | 407 | Europe, US, RoW | IO102-IO103, Pembrolizumab | IO Biotech, Syneos Health, Merck Sharp & Dohme LLC | Metastatic Melanoma, Unresectable Melanoma | 07/25 | 09/27 | | |
CASTLE-02, NCT05057845: Cryoablation Combined With Tislelizumab Plus Lenvatinib as Second-line or Later Therapy in Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 25 | RoW | Tislelizumab, lenvatinib, US/CT-guided Percutaneous Cryoablation | Fudan University | Advanced Hepatocellular Carcinoma | 09/23 | 09/24 | | |
CASTLE-03, NCT05057052: Cryoablation Combined With Sintilimab Plus Regorafenib In Previously Treated Colorectal Cancer Liver Metastasis |
|
|
| Recruiting | 2 | 25 | RoW | Sintilimab, Regorafenib, US/CT-guided Percutaneous Cryoablation | Fudan University | Liver Metastases, Colorectal Cancer Metastatic | 09/23 | 09/24 | | |
NCT05098847: Cryoablation Combined With Sintilimab Plus Lenvatinib In Previously Treated Unresectable Liver Metastasis From Solid Tumors |
|
|
| Recruiting | 2 | 25 | RoW | Sintilimab, Lenvatinib, Cryoablation | Fudan University | Liver Metastasis | 10/23 | 10/24 | | |
NCT04011410: Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer |
|
|
| Active, not recruiting | 2 | 20 | US | Hydroxychloroquine Sulfate 200Mg Tab, Hydroxychloroquine, plaquenil, plaquenil sulfate, quineprox | Patrick Hensley | Prostate Cancer Recurrent | 03/24 | 11/26 | | |
NCT04297280: TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 25 | RoW | Sintilimab, TACE | Fudan University | Hepatocellular Carcinoma | 05/24 | 05/24 | | |
NCT04299581: Cryoablation Combined With Anti-PD-1 Antibody in Patients With Advanced Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 25 | RoW | Camrelizumab, SHR-1210, US/CT-guided Percutaneous Cryoablation | Fudan University | Intrahepatic Cholangiocarcinoma | 05/24 | 05/24 | | |
CHAARTED2, NCT03419234: Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel |
|
|
| Active, not recruiting | 2 | 223 | US | Abiraterone Acetate, CB7630, Zytiga, Antiandrogen Therapy, ADT, Androgen Deprivation Therapy, Anti-androgen Therapy, Anti-androgen Treatment, Antiandrogen Treatment, Hormone Deprivation Therapy, Hormone-Deprivation Therapy, Cabazitaxel, Jevtana, RPR-116258A, Taxoid XRP6258, XRP-6258, Laboratory Biomarker Analysis, Orchiectomy, Castration, Male Castration, Male Gonadectomy, orchidectomy, Pharmacological Study, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisonum, Prednitone, Promifen, Servisone, SK-Prednisone | ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI) | Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Adenocarcinoma AJCC v7 | 09/25 | 04/26 | | |
NCT05406466: Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver Metastasis |
|
|
| Recruiting | 2 | 25 | RoW | Tislelizumab, Lenvatinib, Cryoablation | Fudan University | Melanoma | 07/24 | 08/24 | | |
TASK-02, NCT04954794: TACE Combined with Sintilimab Plus Bevacizumab Biosimilar in Patients with Advanced Hepatocellular Carcinoma |
|
|
| Completed | 2 | 29 | RoW | Sintilimab, TACE | Fudan University | Hepatocellular Carcinoma | 04/24 | 04/24 | | |
CASTLE-01, NCT05010668: Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 25 | RoW | cryoablation, Sintilimab, lenvatinib | Fudan University | Intrahepatic Cholangiocarcinoma | 08/24 | 08/24 | | |
| Recruiting | 2 | 332 | Europe, Canada, Japan, US, RoW | disitamab vedotin, RC48-ADC, pembrolizumab, KEYTRUDA® | Seagen Inc., Merck Sharp & Dohme LLC | Urothelial Carcinoma | 11/26 | 05/28 | | |
NCT04954781: TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 25 | RoW | Tislelizumab, TACE | Fudan University | Intrahepatic Cholangiocarcinoma | 07/25 | 07/25 | | |
NCT05010681: Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer |
|
|
| Recruiting | 2 | 25 | RoW | Sintilimab, Lenvatinib | Fudan University | Intrahepatic Cholangiocarcinoma | 08/25 | 08/25 | | |
CASTLE-08, NCT05781074: Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer （） |
|
|
| Recruiting | 2 | 25 | RoW | Sintilimab, Lenvatinib, Cryoablation | Fudan University | Advanced Biliary Tract Cancer | 12/25 | 12/25 | | |
| Recruiting | 2 | 30 | RoW | Cryoablation, Sintilimab, Lenvatinib | Fudan University | Advanced Intrahepatic Cholangiocarcinoma | 12/25 | 12/25 | | |
OPTIONS-05, NCT05823987: Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer |
|
|
| Recruiting | 2 | 25 | RoW | H101, Oncorine, Tislelizumab, Lenvatinib | Fudan University | Advanced Biliary Tract Cancer | 12/25 | 12/25 | | |
CASTLE-09, NCT05893056: Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Gastric Cancer Liver Metastasis |
|
|
| Recruiting | 2 | 25 | RoW | Cryoablation, Tislelizumab, Lenvatinib | Fudan University | Gastric Cancer Metastatic to Liver | 12/25 | 12/25 | | |
| Recruiting | 2 | 25 | RoW | Cryoablation, Tislelizumab, Lenvatinib | Fudan University | Hepatocellular Carcinoma | 12/25 | 12/25 | | |
| Recruiting | 2 | 25 | RoW | Tislelizumab, Lenvatinib, Cryoablation | Fudan University | Solid Tumor, Adult | 12/25 | 12/25 | | |
ACIT001/EXC002, NCT03938987: Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) |
|
|
| Recruiting | 1/2 | 63 | Canada | autologous CD19-directed chimeric antigen receptor (CAR) T-cells | University of Alberta, Alberta Cancer Foundation, Canadian Cancer Trials Group | Relapsed Non Hodgkin Lymphoma, Relapsed Adult ALL, Relapsed Pediatric ALL | 12/25 | 12/27 | | |
NCT05303844: Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites |
|
|
| Recruiting | 1b | 25 | RoW | H101, Tislelizumab | Fudan University | Refractory Malignant Ascites | 03/25 | 03/25 | | |
NCT05303090: Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer |
|
|
| Recruiting | 1b | 25 | RoW | H101, Tislelizumab, lenvatinib | Fudan University | Pancreatic Ductal Adenocarcinoma | 03/25 | 03/25 | | |
NCT05675462: Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 1b | 25 | RoW | Oncorine, H101, Tislelizumab, Lenvatinib | Fudan University | Hepatocellular Carcinoma | 12/25 | 12/25 | | |
NCT04903119: Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma |
|
|
| Recruiting | 1 | 15 | US | Nilotinib 100mg, Nilotinib 200mg, Nilotinib 300mg, Nilotinib 400mg, Dabrafenib, Trametinib | Ruta Arays, Novartis, National Cancer Institute (NCI) | Metastatic Melanoma, BRAF Gene Mutation | 12/26 | 03/27 | | |
| Recruiting | N/A | 10000 | RoW | | Shanghai Jiao Tong University School of Medicine, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, First Affiliated Hospital Bengbu Medical College, LanZhou University, Henan Cancer Hospital, The First Affiliated Hospital of Zhengzhou University, The Second Affiliated Hospital of Harbin Medical University, First Affiliated Hospital of Harbin Medical University, Harbin Medical University, The First Hospital of Jilin University, Second Hospital of Jilin University, China-Japan Union Hospital, Jilin University, The First People's Hospital of Changzhou, Changzhou No.2 People's Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, The First People's Hospital of Taicang, Wuxi Second People's Hospital, Xuzhou Central Hospital, Second Affiliated Hospital of Suzhou University, Affiliated Hospital of Nantong University, The First People's Hospital of Nantong, The Affiliated Hospital of Xuzhou Medical University, Second Affiliated Hospital of Nanchang University, The First Affiliated Hospital of Nanchang University, Jiangxi Provincial People's Hopital, Shengjing Hospital, Baotou Central Hospital, Qinghai People's Hospital, Changzhi Medical College, The First Affiliated Hospital of Shanxi Medical University, Shanxi Provincial Cancer Hospital, First Affiliated Hospital Xi'an Jiaotong University, Eastern Hepatobiliary Surgery Hospital, Shanghai Fengxian District Central Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Zhongshan Hospital, Shanghai Pudong Hospital, Central Hospital of Minhang District, Shanghai, Putuo District People's Hospital of Shanghai, Xinhua (Chongming) Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Tianjin Medical University Cancer Hospital, First Affiliated Hospital of Xinjiang Medical University, The First Affiliated Hospital of Kunming Medical College, Yinzhou Hospital Affiliated to Medical School of Ningbo University, Shaoxing Second Hospital, Shaoxing People's Hospital, First Affiliated Hospital of Wenzhou Medical University, Sir Run Run Shaw Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Cancer Hospital, Huizhou Municipal Central Hospital, Ningbo No. 1 Hospital, People's Hospital of Hunan Province, Hainan People's Hospital, Taizhou Municipal Hospital, Xinghua City People's Hospital, Tongliao City Hospital, Jiangxi Provincial Cancer Hospital, Shandong Provincial Hospital, Qilu Hospital of Shandong University, The Affiliated Hospital of Qingdao University, Xijing Hospital | Gallbladder Neoplasms | 12/22 | 12/25 | | |
| li, hongyi |
NCT04875169: Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis |
|
|
| Completed | 3 | 336 | Canada, RoW | Core Treatment Active Experimental: SHR0302 Dose#1, Core Treatment Active Experimental: SHR0302 Dose#2, Core Treatment Placebo Comparator: Placebo, Extension Treatment Active Experimental: SHR0302 Dose#1, Extension Treatment Active Experimental: SHR0302 Dose#2 | Reistone Biopharma Company Limited | Atopic Dermatitis | 08/22 | 05/23 | | |
NCT06109818: Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 2 | 129 | RoW | ICP-488 Tablets, ICP-488 Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Moderate to Severe Plaque Psoriasis | 10/24 | 11/24 | | |
| Yuan, Xianglin |
| Recruiting | 4 | 40 | RoW | Hetrombopag Olamine | Huazhong University of Science and Technology | Malignant Tumors of the Digestive System, Trombocitopenia | 10/23 | 12/23 | | |
NCT03236649: The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects |
|
|
| Terminated | 3 | 89 | RoW | Icaritin, Sorafenib Tosylate Tablets | Beijing Shenogen Biomedical Co., Ltd, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Eastern Theater General Hospital,QinHuai District Medical Area, Peking University Cancer Hospital & Institute, Chinese PLA General Hospital, Beijing Hospital, General Hospital of Chinese Armed Police Forces, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Jinan Central Hospital, Linyi Cancer Hospital, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, Nanfang Hospital of Southern Medical University, First People's Hospital of Foshan, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Tianjin Medical University Cancer Institute and Hospital, The Fourth Hospital of Hebei Medical University, Hunan Cancer Hospital, The First Hospital of Jilin University, 307 Hospital of PLA, Fudan University, Henan Cancer Hospital, Jilin Provincial Tumor Hospital, First Affiliated Hospital of Harbin Medical University, First Affiliated Hospital Bengbu Medical College, The First Affiliated Hospital of Soochow University, Tongji Hospital, Beijing YouAn Hospital | Hepatocellular Carcinoma (HCC) | 02/22 | 02/22 | | |
NCT04714190: A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression |
|
|
| Recruiting | 3 | 351 | RoW | RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection, Paclitaxel injection, Taxol, Irinotecan Hydrochloride Injection, CAMPTO, Apatinib Mesylate Tablets, Aitan | RemeGen Co., Ltd. | Gastric Cancer, HER2 Overexpressing Gastric Carcinoma | 12/24 | 06/25 | | |
GAPSO, NCT03801668: Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma |
|
|
| Recruiting | 3 | 294 | RoW | Albumin-bound Paclitaxel plus S-1, Oxaliplatin plus S-1 | Huazhong University of Science and Technology, CSPC Ouyi Pharmaceutical Co., Ltd. | Gastric Cancer | 12/22 | 03/23 | | |
NCT04385550: A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma |
|
|
| Not yet recruiting | 3 | 528 | RoW | Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma | 10/23 | 12/23 | | |
NCT05918094: Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 3 | 540 | RoW | Experimental dose: modified XELOX + sintilimab, Standard dose: standard XELOX + sintilimab | Sun Yat-sen University | Gastric Cancer | 12/26 | 12/28 | | |
NCT05687357: Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma |
|
|
| Recruiting | 2b | 140 | RoW | Tislelizumab, S-1, Oxaliplatin, Nab paclitaxel, Radiation | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Gastric Cancer, Gastroesophageal-junction Cancer | 02/27 | 08/27 | | |
NCT04603040: A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers |
|
|
| Recruiting | 2 | 100 | RoW | Toripalimab, Tuoyi | Shanghai Junshi Bioscience Co., Ltd. | Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy | 12/22 | 03/23 | | |
NCT05438108: SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab in First-line Treatment of mCRC |
|
|
| Recruiting | 2 | 30 | RoW | SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab | Huazhong University of Science and Technology | Metastatic Colorectal Cancer | 01/23 | 01/24 | | |
NCT04294784: Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer |
|
|
| Terminated | 2 | 58 | RoW | Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor), Albumin-bound Paclitaxel | Huazhong University of Science and Technology | Gastric Cancer, GastroEsophageal Cancer | 11/23 | 11/23 | | |
NCT06168786: Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC |
|
|
| Recruiting | 2 | 40 | RoW | Fruquintinib, Cadonilimab, SBRT | Huazhong University of Science and Technology | Colorectal Cancer | 02/26 | 02/27 | | |
NCT06516445: SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC |
|
|
| Recruiting | 2 | 33 | RoW | SCRT, Camrelizumab, Fluzoparib, CAPEOX | Huazhong University of Science and Technology | Colorectal Cancer | 06/25 | 06/26 | | |
NCT06199895: Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer |
|
|
| Recruiting | 2 | 25 | RoW | Paclitaxel Polymeric Micelles for Injection | Liu Huang | Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Stomach Cancer, Esophageal Carcinoma, Breast Cancer | 11/25 | 11/25 | | |
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. |
|
|
| Active, not recruiting | 2 | 103 | RoW | Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan | Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany | BRAF V600E, Metastatic Colorectal Cancer | 12/23 | 01/25 | | |
NCT03941574: A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy |
|
|
| Recruiting | 2 | 108 | RoW | HLX10 | Shanghai Henlius Biotech | MSI-H Solid Malignant Tumor | 05/24 | 06/26 | | |
NCT06632262: A Phase 2 Clinical Study of ABSK061 and ABSK043 |
|
|
| Not yet recruiting | 2 | 202 | RoW | ABSK061 + ABSK043, ABSK061+ABSK043 in combination with CAPOX | Abbisko Therapeutics Co, Ltd | HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors | 11/29 | 06/30 | | |
NCT05934331: A LM-302 Combined With Toripalimab Phase II Study |
|
|
| Recruiting | 2 | 276 | RoW | LM302+Toripalimab, LM302+JS001 | LaNova Medicines Zhejiang Co., Ltd. | Gastric Cancer, Pancreatic Cancer | 07/25 | 01/26 | | |
CT041-ST-01, NCT04581473: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection |
|
|
| Recruiting | 1/2 | 192 | RoW | CT041 autologous CAR T-cell injection, CAR T-cell injection, Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）, Best support care(BSC) | CARsgen Therapeutics Co., Ltd., Peking University Cancer Hospital & Institute, Fudan University | Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma | 06/24 | 06/38 | | |
NCT06592287: The Combination of Adebrelimab, Apatinib, and Lrinotecan Liposome for Second-line Treatment of Advanced Gastric Cancer |
|
|
| Not yet recruiting | 1/2 | 66 | RoW | Adebrelimab + Apatinib + Lrinotecan liposome | Xianglin Yuan | Advanced Gastric Cancer | 09/25 | 09/26 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
KYM901, NCT04805307: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901 |
|
|
| Recruiting | 1 | 162 | RoW | CMG901 | Keymed Biosciences Co.Ltd | Advanced Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Pancreatic Cancer | 05/24 | 10/24 | | |
CIBI343A101, NCT05458219: A First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 470 | US, RoW | IBI343 | Innovent Biologics (Suzhou) Co. Ltd., Innovent Biologics, Inc., TigerMed | Locally Advanced Unresectable or Metastatic Solid Tumors | 12/25 | 12/25 | | |
NCT02490319: Study on the Biological Prediction Models of Radiation Pneumonitis |
|
|
| Recruiting | N/A | 300 | RoW | | Huazhong University of Science and Technology | Radiation Pneumonitis | 07/23 | | | |
NCT06551207: Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC |
|
|
| Recruiting | N/A | 80 | RoW | Fruquintinib, Cadonilimab, SBRT | Liu Huang | Metastatic Colorectal Cancer | 12/26 | 12/27 | | |
NCT05448703: A Study on Predictive Models and Clinical Outcome of Radiation Pneumonitis |
|
|
| Recruiting | N/A | 300 | RoW | Blood Samples for Biomarkers | Huazhong University of Science and Technology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jingjiang People' Hospital | Radiation Pneumonitis | 09/26 | 09/26 | | |
| Shu, Chang |
NCT05003245: Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD |
|
|
| Recruiting | 3 | 388 | RoW | HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis | Shanghai Henlius Biotech | Age Related Macular Degeneration | 08/23 | 03/24 | | |
NCT04275323: Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-1) |
|
|
| Completed | 3 | 302 | RoW | NL003, HGF plasmid, pCK-HGF-X7, Normal Saline, Placebo | Beijing Northland Biotech. Co., Ltd. | Arterial Occlusive Disease, Ischemia, Ulcers, Peripheral Vascular Disease | 06/24 | 06/24 | | |
| Completed | 3 | 242 | RoW | NL003, HGF plasmid, pCK-HGF-X7, Normal Saline, Placebo | Beijing Northland Biotech. Co., Ltd. | Arterial Occlusive Disease, Ischemia, Ulcers, Peripheral Vascular Disease | 12/23 | 12/23 | | |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
NCT06000956: A Study of Comparing Overall Improvement of Patients With Spondyloarthritis Treated With Jitongning Tablets and Placebo |
|
|
| Recruiting | 3 | 408 | RoW | Jitongning tablets, a simulated agent of Jitongning tablets | Tasly Pharmaceutical Group Co., Ltd | Ankylosing Spondylitis | 12/26 | 12/26 | | |
| Recruiting | 2 | 62 | RoW | ABSK-011 180 mg QD combined with atilizumab 1200 mg q3w | Abbisko Therapeutics Co, Ltd | Hepatocellular Carcinoma | 07/24 | 10/24 | | |
NCT06632262: A Phase 2 Clinical Study of ABSK061 and ABSK043 |
|
|
| Not yet recruiting | 2 | 202 | RoW | ABSK061 + ABSK043, ABSK061+ABSK043 in combination with CAPOX | Abbisko Therapeutics Co, Ltd | HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors | 11/29 | 06/30 | | |
PATENCY, NCT03767777: Prospective Study for Aortic Arch Therapy With stENt-graft for Chimney technologY（） |
|
|
| Enrolling by invitation | N/A | 150 | RoW | Artery Stent Graft System | Lifetech Scientific (Shenzhen) Co., Ltd. | Thoracic Aortic Dissection | 06/21 | 12/25 | | |
NCT06725212: Evaluation of the Water Vapor Thermal Therapy System for the Treatment of Benign Prostatic Hyperplasia |
|
|
| Recruiting | N/A | 126 | RoW | Water Vapor Thermal Ablation, Water Vapor Ablation, Cystoscopy | Medtecx Co Ltd. | Benign Prostatic Hyperplasia | 06/25 | 06/26 | | |
NCT05126446: the Aorta Arch Stent Graft System Combined With the Endovascular Needle System in Situ Fenestration |
|
|
| Active, not recruiting | N/A | 120 | RoW | the Aorta Arch Stent Graft System combined with the Endovascular Needle System | Lifetech Scientific (Shenzhen) Co., Ltd. | Aortic Dissection | 10/27 | 03/28 | | |
NCT06520774: Concave Supra-arch Branched Stent-Graft System for Endovascular Treatment of Aortic Arch Diseases |
|
|
| Not yet recruiting | N/A | 103 | NA | Concave Supra-arch Branched Stent-Graft System | Lifetech Scientific (Shenzhen) Co., Ltd., Second Xiangya Hospital of Central South University | Aortic Arch Aneurysm, Penetrating Aortic Ulcer | 10/27 | 10/31 | | |
NCT04765605: Guo's Subclavian Artery Reconstruction: The Prospective, Multiple Center Study of WeFlow-Tbranch Stent Graft System(GUEST Study) |
|
|
| Active, not recruiting | N/A | 120 | RoW | WeFlow-Tbranch Stent Graft System | Hangzhou Endonom Medtech Co., Ltd. | Type B Aortic Dissection | 12/26 | 12/26 | | |
| Chen, Yuan |
| Completed | 2 | 33 | RoW | Apatinib Combined With Tislelizumab and Chemotherapy, Combined therapy | Renmin Hospital of Wuhan University | Advanced Gastric Adenocarcinoma | 03/23 | 01/24 | | |
NCT04952168: Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC |
|
|
| Recruiting | 2 | 26 | RoW | Almonertinib | Yuan Chen | NSCLC, Stage III | 06/22 | 06/23 | | |
| Recruiting | 1/2 | 280 | RoW | SAF-189s, foritinib succinate | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Advanced Cancer, Advanced Solid Tumor, Lung Cancer, Nonsmall Cell | 12/22 | 03/26 | | |
NCT04993391: AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 156 | RoW | JS111(AP-L1898 Capsules) | Suzhou Junjing BioSciences Co., Ltd. | Lung Cancer | 06/24 | 08/24 | | |
NCT04486859: Postoperative Thrombosis Prevention in Patients With CD |
|
|
| Recruiting | N/A | 206 | RoW | LMWH/Rivaroxaban, IPC | Huashan Hospital, Peking Union Medical College Hospital, West China Hospital | Cushing Disease, DVT, Pulmonary Embolism | 02/25 | 05/25 | | |
| Liu, Aiguo |
NCT06434467: The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma |
|
|
| Not yet recruiting | 3 | 83 | RoW | Nelarabine injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | T-lymphoblastic Leukemia, T-lymphoblastic Lymphoma | 12/25 | 05/26 | | |
| Not yet recruiting | 2/3 | 1800 | RoW | Blinatumomab (Group A), high-dose methotrexate, Venetoclax (nonRand Group), cyclophosphamide, vincristine, dexamethasone, Blinatumomab (Group B) | Institute of Hematology & Blood Diseases Hospital, China | Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL) | 12/29 | 06/31 | | |
NCT05334823: A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents |
|
|
| Recruiting | 2 | 100 | RoW | pCAR-19B cells | Chongqing Precision Biotech Co., Ltd | Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia | 12/24 | 07/25 | | |
